Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC cut its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 14.3% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 31,083 shares of the biopharmaceutical company’s stock after selling 5,206 shares during the period. HighTower Advisors LLC’s holdings in Horizon Therapeutics Public were worth $3,271,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Blueshift Asset Management LLC boosted its holdings in shares of Horizon Therapeutics Public by 22.7% in the 1st quarter. Blueshift Asset Management LLC now owns 8,935 shares of the biopharmaceutical company’s stock valued at $940,000 after buying an additional 1,654 shares during the period. 1492 Capital Management LLC boosted its holdings in shares of Horizon Therapeutics Public by 1.5% in the 1st quarter. 1492 Capital Management LLC now owns 121,840 shares of the biopharmaceutical company’s stock valued at $12,819,000 after buying an additional 1,845 shares during the period. King Luther Capital Management Corp boosted its holdings in shares of Horizon Therapeutics Public by 46.8% in the 1st quarter. King Luther Capital Management Corp now owns 14,725 shares of the biopharmaceutical company’s stock valued at $1,549,000 after buying an additional 4,695 shares during the period. US Bancorp DE boosted its stake in Horizon Therapeutics Public by 0.4% during the 1st quarter. US Bancorp DE now owns 44,359 shares of the biopharmaceutical company’s stock valued at $4,667,000 after purchasing an additional 179 shares during the period. Finally, American Century Companies Inc. boosted its stake in Horizon Therapeutics Public by 13.3% during the 1st quarter. American Century Companies Inc. now owns 1,108,197 shares of the biopharmaceutical company’s stock valued at $116,593,000 after purchasing an additional 129,708 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on HZNP shares. SVB Leerink lowered shares of Horizon Therapeutics Public from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. BMO Capital Markets reduced their target price on shares of Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating for the company in a research note on Thursday, August 4th. UBS Group lowered shares of Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and reduced their target price for the company from $137.00 to $71.00 in a research note on Thursday, August 4th. TheStreet lowered shares of Horizon Therapeutics Public from a “b” rating to a “c+” rating in a research note on Tuesday, August 16th. Finally, Morgan Stanley reduced their target price on shares of Horizon Therapeutics Public from $135.00 to $90.00 and set an “overweight” rating for the company in a research note on Thursday, August 4th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $117.22.

Horizon Therapeutics Public Stock Down 1.3 %

HZNP stock opened at $60.00 on Monday. The company has a current ratio of 4.05, a quick ratio of 3.79 and a debt-to-equity ratio of 0.52. The firm’s 50-day moving average is $74.20 and its two-hundred day moving average is $89.56. Horizon Therapeutics Public Limited has a 52 week low of $57.84 and a 52 week high of $120.54. The company has a market capitalization of $13.82 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 1.48 and a beta of 1.12.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.29). Horizon Therapeutics Public had a return on equity of 27.90% and a net margin of 20.06%. The business had revenue of $876.40 million during the quarter, compared to the consensus estimate of $938.82 million. During the same quarter in the previous year, the firm earned $1.62 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, analysts forecast that Horizon Therapeutics Public Limited will post 4.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Horizon Therapeutics Public news, EVP Sean M. Clayton bought 745 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The shares were acquired at an average cost of $66.67 per share, for a total transaction of $49,669.15. Following the acquisition, the executive vice president now directly owns 745 shares of the company’s stock, valued at $49,669.15. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Andy Pasternak sold 4,850 shares of Horizon Therapeutics Public stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $82.57, for a total value of $400,464.50. Following the transaction, the executive vice president now directly owns 34,047 shares of the company’s stock, valued at $2,811,260.79. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Sean M. Clayton bought 745 shares of the company’s stock in a transaction dated Thursday, August 4th. The stock was purchased at an average cost of $66.67 per share, for a total transaction of $49,669.15. Following the completion of the transaction, the executive vice president now owns 745 shares of the company’s stock, valued at $49,669.15. The disclosure for this purchase can be found here. Insiders have sold 5,784 shares of company stock worth $480,133 in the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Horizon Therapeutics Public Company Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Read More

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating).

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.